Uncovering Gain-of-Expression Resistance Drivers for Anti-Cancer Therapies through a Novel Genetic Screening Platform

Join us for a recruitment seminar on March 7 from 2:30 pm - 3:30 pm at Glen site Room EM1.3509

Dr. Kim's headshot

Invited Speaker: Dae-Kyum Kim, Ph.D.
Assistant Professor of Oncology, Kim lab
Department of Cancer Genetics and Genomics, Roswell Park Comprehensive Cancer Center and Genetics, Genomics and Bioinformatics Graduate Program, Jacobs School of Medicine and Biomedical Sciences, State University of New York at Buffalo, Buffalo, New York, USA

Throughout my career, I have focused on the generation and integration of functional genomics data to propose novel hypotheses for experimental validation or new clinical biomarkers. During my undergraduate training, I developed an efficient sequence comparison method to classify proteins with respect to their structures. During my PhD training, I began to explore experimental research. I used well-established high-throughput screening methods such as mass spectrometry and RNA-seq to investigate the proteomic and transcriptomic components of extracellular vesicles and further built a web-based database called EVpedia to facilitate additional research on these biomolecules. During my postdoctoral training, I explored protein–protein interactions systematically to understand various molecular mechanisms underlying human disease. We applied our next-generation sequencing-based yeast-two hybrid techniques to build the Human Reference Interactome (HuRI) that includes ~90% of all human protein-coding genes (Nature 2019). Furthermore, we applied our new barcode sequencing-based yeast two-hybrid to find conditional interactions among yeast proteins under 32 different conditions to discover novel gain of interactions and further identified important protein–protein interactions between SARS-CoV-2 and host proteins (Nature Biotechnology 2023). Now, as a new principal investigator at Roswell Park Comprehensive Cancer Center (from October 2021), I am pursuing the translation of functional genomics tools to precision medicine, by exploring novel approaches to evaluate proteome-scale gene overexpression effects under various conditions to find novel drug combinations to combat chemotherapeutic resistance. Furthermore, our lab is expanding our interest to various biology such as extracellular vesicle biogenesis and delivery, regulation of transcription factor – promoter interaction, autophagy and apoptosis, immunotherapy, etc. I strongly believe this expertise and qualifications will allow me to lead our new group at McGill successfully. 

Back to top